- Home
- WRB vs TEVA Comparison
WRB vs TEVA Comparison
Compare WRB & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRB | TEVA |
|---|---|---|
| Founded | 1967 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.5B | 30.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WRB | TEVA |
|---|---|---|
| Price | $69.52 | $33.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $70.71 | $36.75 |
| AVG Volume (30 Days) | 2.5M | ★ 10.3M |
| Earning Date | 01-26-2026 | 01-28-2026 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | ★ 2.06 | N/A |
| EPS | ★ 4.45 | 1.21 |
| Revenue | $14,707,856,000.00 | ★ $17,258,000,000.00 |
| Revenue This Year | $5.01 | $0.63 |
| Revenue Next Year | $4.72 | $1.67 |
| P/E Ratio | ★ $15.66 | $28.08 |
| Revenue Growth | ★ 7.84 | 4.32 |
| 52 Week Low | $59.55 | $12.47 |
| 52 Week High | $78.96 | $37.35 |
Technical Indicators
Market Signals| Indicator | WRB | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 56.64 | 56.47 |
| Support Level | $68.37 | $34.20 |
| Resistance Level | $73.07 | $34.80 |
| Average True Range (ATR) | 1.84 | 1.13 |
| MACD | 0.40 | -0.17 |
| Stochastic Oscillator | 74.53 | 45.12 |
Price Performance
Historical ComparisonAbout WRB W.R. Berkley Corporation
W.R. Berkley is an insurance holding company with a host of subsidiaries that primarily underwrite commercial casualty insurance. The firm specializes in niche products that include various excess and surplus lines, workers' compensation insurance, self-insurance consulting, reinsurance, and regional commercial lines for small and midsize businesses.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.